103 related articles for article (PubMed ID: 28338310)
1. Metastatic prostate cancer in the modern era of PSA screening.
Fontenot PA; Nehra A; Parker W; Wyre H; Mirza M; Duchene DA; Holzbeierlein J; Thrasher JB; Van Veldhuizen P; Lee EK
Int Braz J Urol; 2017; 43(3):416-421. PubMed ID: 28338310
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
Zagars GK; Pollack A; von Eschenbach AC
Cancer; 1997 Apr; 79(7):1370-80. PubMed ID: 9083160
[TBL] [Abstract][Full Text] [Related]
4. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
Lee WR; Hanks GE; Hanlon A
J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
[TBL] [Abstract][Full Text] [Related]
5. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
6. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
7. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
8. Screening for prostate cancer in New Zealand general practice.
Zuzana O; Ross L; Fraser H; Charis B; Alistair S; Leanne T; Michael H; Peter G
J Med Screen; 2013 Mar; 20(1):49-51. PubMed ID: 23612467
[TBL] [Abstract][Full Text] [Related]
9. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
10. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy.
Pinover WH; Horwitz EM; Hanlon AL; Uzzo RG; Hanks GE
Cancer; 2003 Feb; 97(4):1127-33. PubMed ID: 12569615
[TBL] [Abstract][Full Text] [Related]
11. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
12. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.
Isola J; Auvinen A; Poutiainen M; Kakkola L; Järvinen TA; Määttänen L; Stenman UH; Tammela T; Hakama M; Visakorpi T
J Urol; 2001 May; 165(5):1569-74. PubMed ID: 11342919
[TBL] [Abstract][Full Text] [Related]
13. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
14. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.
Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
Cancer; 2003 Dec; 98(11):2362-7. PubMed ID: 14635070
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen only progression of prostate cancer.
Moul JW
J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
[TBL] [Abstract][Full Text] [Related]
18. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing.
Okihara K; Nakanishi H; Nakamura T; Mizutani Y; Kawauchi A; Miki T
Int J Urol; 2005 Jul; 12(7):662-7. PubMed ID: 16045559
[TBL] [Abstract][Full Text] [Related]
20. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]